Hospital del Mar

Barcelona, Other 08003

0 studies enrolling now · 3 studies all time

What they study most

Diffuse Large B-cell Lymphoma, Hodgkin Lymphoma, Triple Negative Breast Neoplasms

Studies at this site

• Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL — Running, not enrolling
• Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer — Completed
• Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma — Stopped early